Trial Profile
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
- Indications Ductal carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 11 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2011 Planned end date changed from 1 Apr 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.